Eltrombopag for thrombocytopenia in CML
Study title
Eltrombopag for low platelet count associated with TKI in CML [USA]
Scientific title
Eltrombopag for the management of thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia (CML) and myelofibrosis (MF) (ClinicalTrials.gov NCT01428635)
Type of study
Other studies
In a single country
Current status
No longer recruiting patients
What is the purpose of the study
Patients with CML receiving tyrosine kinase inhibitors who develop persistent or profound decrease of platelets (“thrombocytopenia”) are offered eltrombopag together with continuation of their TKI. The goal of this study is to learn if eltrombopag can improve the platelet count in the blood.
Key inclusion criteria
This study includes patients 18 years and older diagnosed with CML in chronic phase. Patients must have been receiving an FDA-approved tyrosine kinase inhibitor (TKI) for at least 3 months.
Patients must have a decrease of platelets in the blood (known as “thrombocytopenia”), grade 3, that is recurrent (at least two episodes) or requiring dose reductions of the tyrosine kinase inhibitor.
Key exclusion criteria
Where can I find additional information
Study description in the US register ClinicalTrials.gov, a service of the U. S. National Institutes of Health
Study sponsor
MD Anderson Cancer Center
Scientific lead / contact
Jorge Cortes
Principal investigator
Gautam Borthakur
Study centers / principal investigators
United States
MD Anderson Cancer Center
University of Texas
Houston, Texas